AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17335366 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgingival chlorhexidine (CHX) varnish administration
Number of subjects: 33
Study 17335366 — intervention group
Group type: COMPARATOR
Intervention: Control group (oral hygiene instructions and same-day full-mouth root planing)
Number of subjects: 33
Study 15204012 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg xaliproden
Number of subjects: 2077
Study 15204012 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg xaliproden
Number of subjects: 2077
Study 15204012 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg xaliproden with riluzole
Number of subjects: 2077
Study 15204012 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2077
Study 12226965 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral strategy to enhance adherence to daily monitoring
Number of subjects: 42
Study 12226965 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 42
Study 9843529 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen supplementation (beta-estradiol 2 mg/tablet, 3 tablets/day for 3 days)
Number of subjects: 21
Study 9843529 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 9843529 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen supplementation
Number of subjects: 21
Study 8305322 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol ointment applied twice daily
Number of subjects: 11
Study 8305322 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment applied twice daily
Number of subjects: 11
Study 8305322 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol
Number of subjects: 11
Study 8305322 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 3059274 — intervention group
Group type: EXPERIMENTAL
Intervention: Pefloxacin 400 mg/day and Penicillin 3 M UI/day
Number of subjects: 65
Study 3059274 — intervention group
Group type: COMPARATOR
Intervention: Cephalothin 250 mg, Gentamicin 20 mg, and Bacitracin 150 UI
Number of subjects: 65
Study 3059274 — intervention group
Group type: EXPERIMENTAL
Intervention: Pefloxacin and Penicillin
Number of subjects: 65
Study 3059274 — intervention group
Group type: COMPARATOR
Intervention: Cephalothin, Gentamicin, and Bacitracin
Number of subjects: 65
Study 31028614 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquablation
Number of subjects: 181
Study 31028614 — intervention group
Group type: COMPARATOR
Intervention: TURP
Number of subjects: 181
Study 29134426 — intervention group
Group type: EXPERIMENTAL
Intervention: Amenamevir 300 mg (single and multiple doses)
Number of subjects: 0
Study 29134426 — intervention group
Group type: EXPERIMENTAL
Intervention: Amenamevir 600 mg (single and multiple doses)
Number of subjects: 0
Study 29134426 — intervention group
Group type: EXPERIMENTAL
Intervention: Amenamevir (various doses, 5-2400 mg)
Number of subjects: 0
Study 29134426 — intervention group
Group type: EXPERIMENTAL
Intervention: Amenamevir with food
Number of subjects: 0
Study 29134426 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet formulation of Amenamevir
Number of subjects: 0
Study 29134426 — intervention group
Group type: EXPERIMENTAL
Intervention: Amenamevir (various doses)
Number of subjects: 0
Study 25284453 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaesthetic digital block with epinephrine (2% mepivacaine with 1:100,000 epinephrine)
Number of subjects: 44
Study 25284453 — intervention group
Group type: COMPARATOR
Intervention: Tourniquet with anaesthetic digital block without epinephrine (2% mepivacaine without epinephrine)
Number of subjects: 44
Study 24491880 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg lipoic acid and 80 mg pyridoxine daily for 12 weeks
Number of subjects: 34
Study 24491880 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 21396703 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec three times a week (starting dose 20 U per injection)
Number of subjects: 245
Study 21396703 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec once a day (starting dose 10 U; group A)
Number of subjects: 245
Study 21396703 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec once a day (starting dose 10 U; group B)
Number of subjects: 245
Study 21396703 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine once a day (starting dose 10 U)
Number of subjects: 245
Study 19905945 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental combined regenerative therapy (ET)
Number of subjects: 60
Study 19905945 — intervention group
Group type: COMPARATOR
Intervention: Open flap debridement (OFD)
Number of subjects: 60
Study 16510646 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (decreased SSB consumption)
Number of subjects: 103
Study 16510646 — intervention group
Group type: COMPARATOR
Intervention: Control group (no change in SSB consumption)
Number of subjects: 103
Study 14628982 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release paroxetine (paroxetine CR) up to 50 mg/day
Number of subjects: 319
Study 14628982 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release paroxetine (paroxetine IR) up to 40 mg/day
Number of subjects: 319
Study 14628982 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 319
Study 15022536 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyrone preoperatively
Number of subjects: 14
Study 15022536 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone and dipyrone preoperatively
Number of subjects: 14
Study 15022536 — intervention group
Group type: COMPARATOR
Intervention: Control group (Dipyrone only)
Number of subjects: 14
Study 10995147 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined rectus sheath and ilioinguinal blocks with bupivacaine 0.25% with adrenaline 1:400,000, up to 60 ml depending on patient's weight.
Number of subjects: 37
Study 10995147 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined rectus sheath and ilioinguinal blocks
Number of subjects: 37
Study 7783888 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium dichloroacetate (DCA) treatment
Number of subjects: 11
Study 2213636 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (5 mg/day) administered at 7 a.m.
Number of subjects: 0
Study 2213636 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (5 mg/day) administered at 11 p.m.
Number of subjects: 0
Study 2213636 — intervention group
Group type: COMPARATOR
Intervention: Control (light therapy not specified in the abstract)
Number of subjects: 0
Study 352200 — intervention group
Group type: EXPERIMENTAL
Intervention: Racemic epinephrine 4.5 mg
Number of subjects: 24
Study 352200 — intervention group
Group type: EXPERIMENTAL
Intervention: Racemic epinephrine 9 mg
Number of subjects: 24
Study 352200 — intervention group
Group type: COMPARATOR
Intervention: Normal subjects (control)
Number of subjects: 24
Study 31014369 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS (1 Hz, 20 sessions, delivered twice a day, 5 days a week for 2 weeks)
Number of subjects: 45
Study 31014369 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS (1 Hz, 20 sessions, delivered twice a day, 5 days a week for 2 weeks)
Number of subjects: 45
Study 31014369 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 45
Study 28516342 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone 10-mg product under fasting conditions
Number of subjects: 24
Study 28516342 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone 10-mg product under fed conditions
Number of subjects: 24
Study 25375652 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 50 mg/d
Number of subjects: 909
Study 25375652 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 100 mg/d
Number of subjects: 909
Study 25375652 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 909
Study 25375652 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine (50 mg/d and 100 mg/d)
Number of subjects: 909
Study 23709010 — intervention group
Group type: EXPERIMENTAL
Intervention: High Intensity Laser Therapy (HILT)
Number of subjects: 48
Study 23709010 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Level Laser Therapy (LLLT)
Number of subjects: 48
Study 23709010 — intervention group
Group type: COMPARATOR
Intervention: Exercise group (Control)
Number of subjects: 48
Study 22524834 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation plus chemotherapy (TP) group (Taxotere 35 mg/m2 once weekly, Cisplatin 20 mg/m2 once weekly)
Number of subjects: 56
Study 22524834 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (RT) group
Number of subjects: 56
Study 19602880 — intervention group
Group type: EXPERIMENTAL
Intervention: ERN/LRPT 1 g/20 mg
Number of subjects: 332
Study 19602880 — intervention group
Group type: COMPARATOR
Intervention: N-ER 1 g (Niaspan(R))
Number of subjects: 332
Study 19602880 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 332
Study 17331753 — intervention group
Group type: COMPARATOR
Intervention: 20% benzocaine gel
Number of subjects: 40
Study 17331753 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% lidocaine/2.5% prilocaine (EMLA) cream
Number of subjects: 40
Study 17331753 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% lidocaine/2.5% prilocaine (Oraqix) gel
Number of subjects: 40
Study 15672120 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium dobesilate 1000 mg/day
Number of subjects: 0
Study 15672120 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium dobesilate 2000 mg/day
Number of subjects: 0
Study 15672120 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15672120 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium dobesilate (both dosages)
Number of subjects: 0
Study 11988029 — intervention group
Group type: EXPERIMENTAL
Intervention: LCPUFA supplementation of infant formulas
Number of subjects: 0
Study 11988029 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention trials extending beyond the first two years of life
Number of subjects: 0
Study 11988029 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention to selection and attrition biases
Number of subjects: 0
Study 9541154 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg/day venlafaxine
Number of subjects: 358
Study 9541154 — intervention group
Group type: EXPERIMENTAL
Intervention: 225 mg/day venlafaxine
Number of subjects: 358
Study 9541154 — intervention group
Group type: EXPERIMENTAL
Intervention: 375 mg/day venlafaxine
Number of subjects: 358
Study 9541154 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 358
Study 8014524 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemophilus influenzae type b capsular polysaccharide-tetanus toxoid conjugate vaccine (PRP-T)
Number of subjects: 10000
Study 8014524 — intervention group
Group type: EXPERIMENTAL
Intervention: Reconstituted lyophilized PRP-T vaccine
Number of subjects: 10000
Study 8014524 — intervention group
Group type: COMPARATOR
Intervention: PRP-T vaccine
Number of subjects: 10000
Study 2600748 — intervention group
Group type: EXPERIMENTAL
Intervention: Freeze-dried dura mater allografts (FDDMA)
Number of subjects: 7
Study 2600748 — intervention group
Group type: COMPARATOR
Intervention: Host flap (RF)
Number of subjects: 7
Study 28750968 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard push-up plus (SPP)
Number of subjects: 15
Study 28750968 — intervention group
Group type: EXPERIMENTAL
Intervention: Wall push-up plus (WPP)
Number of subjects: 15
Study 28750968 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric horizontal abduction (IHA) application during SPP
Number of subjects: 15
Study 28750968 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric horizontal abduction (IHA) application during WPP
Number of subjects: 15
Study 26447350 — intervention group
Group type: EXPERIMENTAL
Intervention: Crystalline short-chain α-glucan (CSCA)
Number of subjects: 10
Study 26447350 — intervention group
Group type: EXPERIMENTAL
Intervention: Waxy maize starch
Number of subjects: 10
Study 23416219 — intervention group
Group type: EXPERIMENTAL
Intervention: Restorative home care services (goal facilitation tool, individually tailored activity programs)
Number of subjects: 205
Study 23416219 — intervention group
Group type: COMPARATOR
Intervention: Usual care (standard needs assessment)
Number of subjects: 205
Study 21204607 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetrorelix (CTX) 3.0 mg
Number of subjects: 6
Study 18762208 — intervention group
Group type: EXPERIMENTAL
Intervention: NHTG2 (4 mg)
Number of subjects: 0
Study 18762208 — intervention group
Group type: COMPARATOR
Intervention: NHTG1
Number of subjects: 0
Study 18762208 — intervention group
Group type: COMPARATOR
Intervention: Nicorette FreshMint
Number of subjects: 0
Study 17382162 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-suture anastomosis technique (group 1)
Number of subjects: 90
Study 17382162 — intervention group
Group type: COMPARATOR
Intervention: Four-suture anastomosis technique (group 2)
Number of subjects: 90
Study 17382162 — intervention group
Group type: COMPARATOR
Intervention: Six-suture anastomosis technique (group 3)
Number of subjects: 90
Study 17382162 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 90
Study 15619966 — intervention group
Group type: EXPERIMENTAL
Intervention: Pericardial suction blood (PSB) using conventional cardiotomy suction retransfusion
Number of subjects: 60
Study 15619966 — intervention group
Group type: EXPERIMENTAL
Intervention: Pericardial suction blood (PSB) after cell-saver processing
Number of subjects: 60
Study 15619966 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study 11204294 — intervention group
Group type: EXPERIMENTAL
Intervention: Indexation of left ventricular mass using bioelectrical impedance-determined fat-free mass (FFM)
Number of subjects: 1371
Study 11204294 — intervention group
Group type: EXPERIMENTAL
Intervention: Indexation of left ventricular mass using approximated fat-free mass (FFMa)
Number of subjects: 1371
Study 11204294 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender-specific equations for predicting FFM
Number of subjects: 1371
Study 9593024 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine group (2 doses of whole, killed promastigote vaccine cocktail plus BCG adjuvant)
Number of subjects: 844
Study 9593024 — intervention group
Group type: COMPARATOR
Intervention: Control group (2 doses of BCG only)
Number of subjects: 844
Study 9593024 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine group
Number of subjects: 844
Study 9593024 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 844
Study 7821196 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist-Erb point conduction velocity (WECV)
Number of subjects: 38
Study 7821196 — intervention group
Group type: EXPERIMENTAL
Intervention: EP-N13 interpeak latency
Number of subjects: 38
Study 7821196 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between WECV and EP-N13 interpeak latency
Number of subjects: 38
Study 7821196 — intervention group
Group type: EXPERIMENTAL
Intervention: WECV correlation with motor and sensory peripheral nerve conduction velocities
Number of subjects: 38
Study 7821196 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between peripheral parameters and EP-N13 interpeak latency
Number of subjects: 38
Study 3136608 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 X 10(9) bacterial equivalents (BE)
Number of subjects: 36
Study 3136608 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 X 10(9) BE
Number of subjects: 36
Study 3136608 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.6 X 10(9) BE
Number of subjects: 36
Study 3136608 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 3136608 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.6 X 10(9) BE (on days 0 and 28)
Number of subjects: 36
Study 3136608 — intervention group
Group type: EXPERIMENTAL
Intervention: All concentrations of vaccine
Number of subjects: 36
Study 3136608 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with high pre‐immunisation‐titres
Number of subjects: 36
Study 3136608 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with low pre‐immunisation‐titres
Number of subjects: 36
Study 3136608 — intervention group
Group type: EXPERIMENTAL
Intervention: ELISA titre
Number of subjects: 36
Study 31837276 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised home exercise jaw opening and chewing programmes, and home oral hygiene measures instructed and controlled by a trained dentist.
Number of subjects: 29
Study 31837276 — intervention group
Group type: COMPARATOR
Intervention: Control period without intervention.
Number of subjects: 29
Study 30735139 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based healthy lifestyle program (Time2bHealthy) for 11 weeks, followed by fortnightly emails for 3 months.
Number of subjects: 86
Study 30735139 — intervention group
Group type: COMPARATOR
Intervention: Comparison group received email communication only.
Number of subjects: 86
Study 28604618 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans-resveratrol (2 × 75 mg/day) for 4 weeks
Number of subjects: 45
Study 28604618 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules for 4 weeks
Number of subjects: 45
Study 25698163 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 53
Study 25698163 — intervention group
Group type: COMPARATOR
Intervention: Prescriptive Advice (PA)
Number of subjects: 53
Study 25698163 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 53
Study 24014603 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicular flushing
Number of subjects: 50
Study 24014603 — intervention group
Group type: COMPARATOR
Intervention: Direct aspiration
Number of subjects: 50
Study 21320084 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided interscalene or supraclavicular nerve blocks
Number of subjects: 257
Study 21320084 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 257
Study 17439539 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate (BDP) aerosols with MMAD of 1.5 microm
Number of subjects: 10
Study 17439539 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate (BDP) aerosols with MMAD of 2.5 microm
Number of subjects: 10
Study 17439539 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate (BDP) aerosols with MMAD of 4.5 microm
Number of subjects: 10
Study 16307696 — intervention group
Group type: EXPERIMENTAL
Intervention: Metopimazine (15 mg tid) with methylprednisolone (48 mg)
Number of subjects: 99
Study 16307696 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron (8 mg bid) with methylprednisolone (48 mg)
Number of subjects: 99
Study 11950706 — intervention group
Group type: EXPERIMENTAL
Intervention: Low HDL levels (hyperlipidemic)
Number of subjects: 65
Study 11950706 — intervention group
Group type: EXPERIMENTAL
Intervention: Low HDL levels (normolipidemic)
Number of subjects: 65
Study 11950706 — intervention group
Group type: COMPARATOR
Intervention: Average HDL levels (hyperlipidemic)
Number of subjects: 65
Study 11950706 — intervention group
Group type: COMPARATOR
Intervention: Average HDL levels (normolipidemic)
Number of subjects: 65
Study 11950706 — intervention group
Group type: COMPARATOR
Intervention: High HDL levels
Number of subjects: 65
Study 11950706 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate treatment in 20 low-HDL subjects
Number of subjects: 65
Study 10710176 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin treatment (low doses in the afternoon)
Number of subjects: 5
Study 10710176 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 5
Study 7628885 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term oral anticoagulant treatment after myocardial infarction
Number of subjects: 350
Study 7628885 — intervention group
Group type: COMPARATOR
Intervention: Eligible non-participants
Number of subjects: 350
Study 2487802 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg a day
Number of subjects: 44
Study 2487802 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine retard 20 mg b.i.d.
Number of subjects: 44
Study 2487802 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg and Nifedipine retard 20 mg once a day
Number of subjects: 44
Study 937070 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive ultrasound Doppler technique
Number of subjects: 35
Study 31629805 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib cream 1.5% BID
Number of subjects: 307
Study 31629805 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 307
Study 27689690 — intervention group
Group type: EXPERIMENTAL
Intervention: foam-fluid hybrid cushions
Number of subjects: 78
Study 27689690 — intervention group
Group type: COMPARATOR
Intervention: air-filled and foam cushions
Number of subjects: 78
Study 27301456 — intervention group
Group type: EXPERIMENTAL
Intervention: PLA2G7 V279F variant
Number of subjects: 91428
Study 25516316 — intervention group
Group type: EXPERIMENTAL
Intervention: Turmeric (1 g)
Number of subjects: 48
Study 25516316 — intervention group
Group type: COMPARATOR
Intervention: Cinnamon (2 g)
Number of subjects: 48
Study 25516316 — intervention group
Group type: EXPERIMENTAL
Intervention: Turmeric (1 g) with white bread
Number of subjects: 48
Study 22883034 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified human milk (FHM)
Number of subjects: 125
Study 22883034 — intervention group
Group type: COMPARATOR
Intervention: Preterm formula
Number of subjects: 125
Study 20557267 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin
Number of subjects: 0
Study 20557267 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18362932 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg ranibizumab
Number of subjects: 40
Study 18362932 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab
Number of subjects: 40
Study 16026656 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week multiple risk modification group program
Number of subjects: 184
Study 16026656 — intervention group
Group type: COMPARATOR
Intervention: Usual care with standard physical exercise training
Number of subjects: 184